Document Detail


The use of prostacyclin, PGI2, in the prevention of platelet aggregation during charcoal haemoperfusion.
MedLine Citation:
PMID:  378864     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In previous studies severe side effects, including irreversible hypotension, platelet losses and rises in Swank screen filtration pressure, have been recorded during the treatment by charcoal haemoperfusion of patients with fulminant hepatic failure. It has also been demonstrated that rises in Swank screen filtration pressure in an in vitro test circuit are due to the presence of platelet aggregates. In this study Prostacyclin was infused at a constant rate, to give a blood concentration of 5 ng/ml, into the in vitro circuit just prior to the charcoal column. Rises in Swank screen filtration pressure were prevented, and it was also shown that the giving of a bolus dose of Prostacyclin (400 ng/ml blood concentration) reversed rises in Swank screen filtration pressure that have already occurred. On the basis of these findings, Prostacyclin would be expected to be of considerable clinical value in the prevention of adverse platelet reactions to charcoal haemoperfusion when carried out in patients with fulminant hepatic failure.
Authors:
P G Langley; R D Hughes; H Y Ton; D B Silk; R Williams
Related Documents :
6324324 - Drug stimulated prostacyclin release.
3523624 - Prostacyclin and thromboxane formation in human umbilical arteries following stimulatio...
8761344 - Inhibition of platelet aggregation by endocardial endothelial cells.
1333254 - Ace-inhibition, kinins, and vascular pgi2 synthesis.
1966624 - Effect of increasing estradiol levels on platelet peripheral benzodiazepine binding sit...
18485494 - In vitro susceptibility of sea lion poxvirus to cidofovir.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The International journal of artificial organs     Volume:  2     ISSN:  0391-3988     ISO Abbreviation:  Int J Artif Organs     Publication Date:  1979 Jul 
Date Detail:
Created Date:  1979-09-25     Completed Date:  1979-09-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7802649     Medline TA:  Int J Artif Organs     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  207-10     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Diphosphate / pharmacology
Charcoal / therapeutic use
Epoprostenol / pharmacology*
Hemoperfusion / methods*
Humans
Liver Diseases / therapy
Platelet Aggregation / drug effects*
Prostaglandins / pharmacology*
Thromboembolism / prevention & control
Chemical
Reg. No./Substance:
0/Prostaglandins; 16291-96-6/Charcoal; 35121-78-9/Epoprostenol; 58-64-0/Adenosine Diphosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antigen and mitogen induced production of macrophage migration inhibitory factor in the mouse.
Next Document:  Hodgkin's disease in patients with previous infectious mononucleosis.